Clinical Report: The Evolving TKI Pipeline
Overview
Expand on the treatment burden aspects and clarify the comparison with anti-VEGF agents.
Background
The introduction of anti-VEGF agents revolutionized the management of retinal vascular diseases, yet these treatments impose significant burdens on healthcare systems and patients. TKIs, which target various angiogenic pathways, are being investigated to enhance treatment durability and reduce the frequency of injections. Understanding the clinical potential of TKIs is crucial as the field seeks to improve patient outcomes and optimize treatment regimens.
Data Highlights
| Agent | Trial Phase | Key Findings |
|---|---|---|
| Duravyu (EYP-1901) | Phase 2 DAVIO 2 | Noninferior BCVA outcomes vs aflibercept |
| OTX-TKI (Axpaxli) | Phase 1/2 | Comparable BCVA and CST outcomes vs aflibercept |
| CLS-AX | Phase 1/2 OASIS | Stable BCVA and CST, reduced need for aflibercept |
Key Findings
- TKIs have a broad range of targets, potentially leading to increased duration of action.
- Duravyu demonstrated statistically noninferior BCVA outcomes compared to aflibercept in the DAVIO 2 trial.
- OTX-TKI showed comparable efficacy to aflibercept in both nAMD and DME trials.
- CLS-AX maintained stable BCVA and CST, with significant reductions in additional aflibercept therapy requirements.
- Phase 3 trials for several TKIs are underway, with results expected in the coming years.
Clinical Implications
The development of TKIs may offer a promising alternative to current anti-VEGF therapies, potentially reducing the frequency of injections and overall treatment burden for patients. Clinicians should stay informed about ongoing trials and emerging data to optimize treatment strategies for retinal vascular diseases.
Conclusion
The evolving TKI pipeline represents a significant advancement in the treatment of retinal vascular diseases, with the potential to improve patient outcomes and reduce healthcare burdens. Continued research and clinical trials will be essential to validate these findings and integrate TKIs into standard care.
References
- EyePoint Pharmaceuticals, EyePoint Pharmaceuticals, 2023 -- Positive Topline Data from the Phase 2 DAVIO 2 Trial
- Retinal Physician, Retinal Physician, 2025 -- Tyrosine Kinase Inhibitors in Retinal Exudative Diseases
- Oregon Health & Science University, Oregon Health & Science University, 2025 -- Age-Related Macular Degeneration Preferred Practice Pattern
- PubMed, PubMed, 2023 -- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab
- Archives of Toxicology — Recent Advances in the Inhibition and Induction of CYP Enzymes in Humans
- retinal physician — The Promise of TKIs
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 - PubMed
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints - EyePoint Pharmaceuticals
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.